Lakefront Biotherapeutics American Depositary Shares
LKFT
132 hedge funds and large institutions have $506M invested in Lakefront Biotherapeutics American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
108% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 24
95% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 19
14% more funds holding
Funds holding: 116 → 132 (+16)
12% more capital invested
Capital invested by funds: $452M → $506M (+$53.8M)
3.05% more ownership
Funds ownership: 6.96% → 10.02% (+3.1%)
64% less call options, than puts
Call options by funds: $31.4M | Put options by funds: $87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$53.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.2M |
| 3 |
O
OrbiMed
New York
|
+$21.3M |
| 4 |
Goldman Sachs
New York
|
+$20.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$22.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.1M |
| 3 |
Citigroup
New York
|
-$9.21M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.43M |
| 5 |
Renaissance Technologies
New York
|
-$5.92M |
LKFT Hedge Fund Activity: Q1 2021 in Review
132 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2021, worth a combined $506M — up 12% from $452M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new LKFT positions and 19 closed out — a net gain of 18 holders — while 50 added to existing stakes and 24 trimmed.
The largest buyer was Capital International Investors, adding an estimated $53.8M. The largest seller was BlackRock, cutting an estimated $22.8M.
- 132 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2021, up from 116 in Q4 2020.
- Funds reported $506M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2021, up 12% quarter-over-quarter.
- 37 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2021 and 19 closed out, a net change of +18 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2021 was Capital International Investors, an estimated $53.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2021 was BlackRock, an estimated $22.8M sold.
Based on aggregated 13F filings for Q1 2021.